Projects Archive - Page 3 of 4 - Sickle Cell Disease Association of America Inc.

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation...

Happy Holidays from SCDAA!

The Board of Directors and the staff of the Sickle Cell Disease Association of America, Inc. wish you and your families a safe...

NBC News Covers the Signing of the Sickle Cell Treatment Act of 2018!

NBC News reporter Chandelis R. Duster wrote an article covering the signing of the Sickle Cell Treatment Act of 2018! Below...

The President Signs the Sickle Cell Treatment Act of 2018!

Advocacy Efforts Create Legislative Victory! On December 18, 2018, S.2465 – The Sickle Cell Disease and Other Heritable Blood Disorders Research,...

Read a New Abstract on Camps for Children With Sickle Cell!

Written by Dr. Lewis Hsu, the SCDAA’s Vice Chief Medical Officer, the abstract below is included in a new article published...

Cincinnati Children’s Hospital Announces 2019 Hemoglobinopathy Counselor Training Course!

For over 10 years, Cincinnati Children’s Hospital Medical Center has offered a comprehensive hemoglobinopathy counselor training course to educate and train...